Takeda Expands Antibody Collaboration With Xoma
This article was originally published in The Pink Sheet Daily
Executive Summary
Agreement now could earn California company $230 million before royalties for identifying therapeutic antibodies that target cancer.
You may also be interested in...
Pfizer Licenses Xoma’s BCE Antibody Technology
Xoma to receive $30 million up-front payment.
Pfizer Licenses Xoma’s BCE Antibody Technology
Xoma to receive $30 million up-front payment.
Xoma Launches Phase I Trial Of Monoclonal Antibody Diabetes Therapy
Xoma 052 targets interleukin-1 beta to stop destruction of pancreatic cells.